N/A N=7 Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab
Psoriasis
Primary: Change in Psoriasis Area Severity Index (PASI-75) — 1; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=557 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Overactive Bladder
Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.47; 5.09; -2.65; -0.87 Incontinence episodes
Phase 3 N=449 Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series…
N/A N=192 Effectiveness of Incorporating Tai Chi in Pulmonary Rehabilitation Program for Chronic Obstructive Pulmonary Disease Patients in Primary Health Care
Chronic Obstructive Pulmonary Disease
Primary: Self Efficacy :COPD Self Efficacy Scale (CSES) — 0.733; 0.685 rating score of 0.2 to 1 — p=0.252
Phase 4 N=40 Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants
Schizophrenia
Primary: Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale at Week 10 — 3.55; 0.82 Units on a scale — p=0.000
Phase 2 N=43 Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Responders (Complete and Partial Response) — 8; 18 participants
Phase 3 N=548 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Overactive Bladder
Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.52; 5.70; -2.95; -1.03 Incontinence episodes
Phase 4 N=20 A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3. — -0.72 Scores on a scale
Phase 2 N=26 Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma
Asthma
Primary: Emax: Maximum Value of FEV1 for Every Treatment Visits — 3.788; 3.784; 3.756; 3.763 Liters
N/A N=32 A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand
Corneal Staining
Primary: Corneal Staining Severity — 0.01; 0.01; 0.02; 0.01 units on a scale
Phase 3 N=30 Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
Acne Vulgaris
Primary: Percent Change in Truncal Lesion Counts — 52.1; -9.2; 53.2; 18.2 percentage change of lesions
Phase 4 N=22 Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin
Healthy
Primary: Drape Adhesion — 78.6; 181.3 grams-force
Phase 2 N=310 Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
Chronic Constipation
Primary: Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency — 2.59; 3.25; 3.57; 4.29 SBMs per week — p=0.0337
Phase 2 N=52 Treatment of Depression in Parkinson's Disease Trial
Parkinson Disease · Depression
Primary: Hamilton Depression Scale — 10.84; 12.45; 15.81 units on a scale
Phase 2 N=172 Targeted Interventions for Weight-Concerned Smokers
Nicotine Dependence
Primary: Weight Gain at 26 Weeks. — 6.75; 9.71 pounds